{"id":"W3034504576","doi":"10.1093/crocol/otaa049","title":"Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis","year":2020,"lang":"en","type":"article","venue":"Crohn s & Colitis 360","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"Kyowa Kirin Pharmaceutical Development","keywords":"Medicine; Placebo; Ulcerative colitis; Gastroenterology; Clinical endpoint; Internal medicine; Adverse effect; Pharmacodynamics; Ascending colon; Phases of clinical research; Monoclonal antibody; Population; Randomized controlled trial; Pharmacokinetics; Clinical trial; Surgery; Antibody; Immunology; Pathology; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002174044,0.002022802,0.003012517,0.0005432907,0.000545935,0.001191821,0.001139908,0.002205513,0.006633467],"category_scores_gemma":[0.001826728,0.00100582,0.001092025,0.0004463984,0.001101704,0.001103236,0.0005135434,0.003024026,0.001361248],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006066842,"about_ca_system_score_gemma":0.001563032,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000560527,"about_ca_topic_score_gemma":0.001441872,"domain_scores_codex":[0.9992359,0.0004029744,0.00004110456,0.0001331163,0.00006995975,0.000117005],"domain_scores_gemma":[0.9988405,0.0002522514,0.0002612744,0.0001330934,0.000127002,0.0003858443],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9515474,0.02002184,0.0007185054,0.0004394944,0.0004193361,0.0000598,0.00007970251,0.0002848375,0.01155089,0.00008417146,0.001088046,0.01370584],"study_design_scores_gemma":[0.9080798,0.08907434,0.001348875,0.00001203813,0.0001348301,0.00003211068,0.000009908113,0.0001990889,0.0004712911,0.00006233127,0.0005658938,0.000009331292],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9777038,0.002865454,0.001662028,0.0009442327,0.0006280089,0.01160167,0.002006641,0.0003673598,0.002220917],"genre_scores_gemma":[0.9609484,0.002691816,0.006091722,0.002759414,0.0008245712,0.01670988,0.002744415,0.00009057525,0.007139265],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006633467,"threshold_uncertainty_score":0.02219111,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02534543814436496,"score_gpt":0.3252506905611766,"score_spread":0.2999052524168116,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}